BD closes TVA Medical buy

Becton Dickinson (NYSE:BDX) wasted no time in closing the cash buyout of  TVA Medical, which just a few weeks ago landed FDA clearance for its EverlinQ EndoAVF hemodialysis device, for an undisclosed amount. Austin, Texas-based TVA won de novo clearance June 22 for the EverlinQ EndoAVF device, which uses a pair of magnetic catheters and radiofrequency energy to create an arteriovenous fistula for hemodialysis access without open surgery. BD said today that it plans to change the system’s name to WavelinQ EndoAVF as it integrates TVA into its peripheral intervention business. “The FDA’s authorization and joining BD are the culmination of many years of hard work by a dedicated team of innovators at TVA Medical and I’d like to thank them for their tireless efforts to get us to these important milestones,” co-founder Adam Berman said in prepared remarks. “BD will enable us to deliver to physicians and patients what we believe is a highly desirable and transformative endovascular technology as an integral part of a broader [end-stage renal disease]-focused portfolio of solutions. I look forward to the next chapter of our history as part of the BD family.” “The addition of TVA Medical allows BD to provide another innovative device to physicians who treat patients suffering from chronic kidney disease requiring hemodialysis,” added peripheral intervention president Steve Williamson. “This technology is h...
Source: Mass Device - Category: Medical Devices Authors: Tags: Dialysis Mergers & Acquisitions bectondickinson TVA Medical Source Type: news

Related Links:

AbstractBackgroundIron deficiency is a common cause of anemia in pediatric patients with hemodialysis-dependent chronic kidney disease (CKD-5HD). Ferric pyrophosphate citrate (FPC, Triferic ®) donates iron directly to transferrin, bypassing the reticuloendothelial system and avoiding iron sequestration. Administration of FPC via dialysate or intravenously (IV) may provide a suitable therapeutic option to current IV iron preparations for these patients.MethodsThe pharmacokinetics and safety of FPC administered via dialysate and IV to patients aged
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research
ConclusionsIn pediatric dialysis patients, ferric citrate may be able to concurrently lower phosphate levels and treat iron deficiency. However, larger studies are needed to further evaluate safety and efficacy in the pediatric chronic kidney disease population.
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research
ConclusionsOur findings support the presence of erythropoiesis inhibitory substances in uremic sera. EPO/EPO-R-dependent mechanisms may play a role in inhibiting erythropoiesis. The in vitro bioassay described herein may serve as an indicator of rHuEPO responsiveness which may encourage further investigation of underlying mechanisms of EPO resistance.
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research
Conclusion: Community acquired AKI is a major health problem with high morbidity and mortality.Nephron
Source: Nephron - Category: Urology & Nephrology Source Type: research
Z, Tesař V, Vokurka M Abstract Hepcidin is a key regulator of iron metabolism and plays an important role in many pathologies. It is increased by iron administration and by inflammation, while erythropoiesis downregulates its expression. It decreases iron availability and thus contributes to anemia of chronic diseases. The aim of the study was to measure hepcidin as a marker and pathogenic factor in ANCA-associated vasculitis (AAV). Hepcidin plasma concentration was measured by the immunological method in 59 patients with AAV and compared to patients with non-vasculitic etiology of chronic kidney disease, patien...
Source: Physiological Research - Category: Physiology Authors: Tags: Physiol Res Source Type: research
PM Sohal, A Goel, D Gupta, N Aslam, J Sandhu, JS Sandhu, EE John, D SharmaIndian Journal of Nephrology 2018 28(5):335-338 Hemodialysis patients are at higher risk of cardiovascular disease due to traditional and dialysis-related risk factors. Our aim was to study the effects of hemodialysis on the corrected QT interval (QTc) and QTc dispersion in chronic kidney disease (CKD) without clinically manifest heart disease. Two hundred cases of CKD on chronic intermittent hemodialysis of >3 months' duration were included in the study. Twelve-lead electrocardiography and samples for serum creatinine, potassium, calcium, a...
Source: Indian Journal of Nephrology - Category: Urology & Nephrology Authors: Source Type: research
Conclusions: Switching to RetacritTM was non-inferior to continuing ­Epogen® in maintaining hemoglobin levels in patients receiving hemodialysis, when both ESAs were dosed using a specified algorithm (ClinicalTrials.gov, NCT02504294).Am J Nephrol 2018;48:214 –224
Source: American Journal of Nephrology - Category: Neurology Source Type: research
Conclusions: TP0463518 induced dose-dependent EPO production, mainly derived from the liver in HV and CKD patients. These results suggest that TP0463518 is a new strategy for treating anemia in CKD, which can be used regardless of renal functions.Am J Nephrol 2018;48:157 –164
Source: American Journal of Nephrology - Category: Neurology Source Type: research
CONCLUSIONS: Switching to RetacritTM was non-inferior to continuing -Epogen® in maintaining hemoglobin levels in patients receiving hemodialysis, when both ESAs were dosed using a specified algorithm (ClinicalTrials.gov, NCT02504294). PMID: 30196301 [PubMed - as supplied by publisher]
Source: American Journal of Nephrology - Category: Urology & Nephrology Authors: Tags: Am J Nephrol Source Type: research
CONCLUSIONS: TP0463518 induced dose-dependent EPO production, mainly derived from the liver in HV and CKD patients. These results suggest that TP0463518 is a new strategy for treating anemia in CKD, which can be used regardless of renal functions. PMID: 30176654 [PubMed - as supplied by publisher]
Source: American Journal of Nephrology - Category: Urology & Nephrology Authors: Tags: Am J Nephrol Source Type: research
More News: Chronic Kidney Disease | Dialysis | Hemodialysis | Mergers and Aquisitions | Urology & Nephrology